Loading...
Market
Novartis achieves clinical milestone with Mariana's drug by May 2024?
5
Resolution / Starting Odds
Yes • 50%
No • 50%
Novartis official press releases or major healthcare news outlets
Story
Novartis Buys Private U.S. Radiopharma Firm Mariana Oncology for $1.75B
May 2, 2024, 11:29 AM
Novartis has announced the acquisition of U.S. private radiopharmaceutical company Mariana Oncology for $1 billion, with an additional up to $750 million contingent on milestones. This strategic move aims to strengthen Novartis' position in the radioligand therapy (RLT) space, enhancing its pipeline of drugs targeting cancer cells specifically. The acquisition, backed by investors including Atlas Venture, Access Biotechnology, and RA Capital Management, is part of Novartis' broader strategy to expand its leadership in the radiopharmaceutical field, where it already produces leading drugs.
View original story
Similar markets
Pfizer • 25%
Johnson & Johnson • 25%
Roche • 25%
Novartis • 25%
FDA approval for another drug • 33%
Major partnership announcement • 33%
No major milestone • 33%